The Delhi high court has restrained Glenmark Pharmaceuticals from selling two diabetes drugs - Zita and Zita-Met – stating the company has infringed Merck Sharp and Dohme’s (MSD) patent on the main ingredient, Sitagliptin. Earlier, in an interim order, a division bench of the High Court had restrained Glenmark from making or selling its drug, used for treatment of Type-II diabetes.
“As per the court's order on October 7, 2015, Glenmark has been restrained by a decree of permanent injunction from making, using, selling, distributing, advertising, exporting, offering for sale or dealing in Sitagliptin Phosphate Monohydrate or any other salt of Sitagliptin in any form, alone or in combination with one or more other drugs,” said Glenmark in a BSE filing.
Glenmark said that it was evaluating the possible legal options to appeal against the decision.
